18554 Federal Register / Vol. 76, No. 64 / Monday, April 4, 2011 / Notices 

Daniel Holcomb, 

Reports Clearance Officer, Centers for Disease 

Control and Prevention. 

[FR Doc. 2011–7888 Filed 4–1–11; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60Day-11–11DT] 

Proposed Data Collections Submitted 

for Public Comment and 

Recommendations 

In compliance with the requirement 

of Section 3506(c)(2)(A) of the 

Paperwork Reduction Act of 1995 for 

opportunity for public comment on 

proposed data collection projects, the 

Centers for Disease Control and 

Prevention (CDC) will publish periodic 

summaries of proposed projects. To 

request more information on the 

proposed projects or to obtain a copy of 

the data collection plans and 

instruments, call 404–639–5960 or send 

comments to Daniel Holcomb, CDC 

Reports Clearance Officer, 1600 Clifton 

Road, MS–D74, Atlanta, GA 30333 or 

send an e-mail to omb@cdc.gov. 

Comments are invited on: (a) Whether 

the proposed collection of information 

is necessary for the proper performance 

of the functions of the agency, including 

whether the information shall have 

practical utility; (b) the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information; (c) 

ways to enhance the quality, utility, and 

clarity of the information to be 

collected; and (d) ways to minimize the 

burden of the collection of information 

on respondents, including through the 

use of automated collection techniques 

or other forms of information 

technology. Written comments should 

be received within 60 days of this 

notice. 

Proposed Project 

Monitoring Outcomes of the 

Enhanced Comprehensive HIV 

Prevention Planning (ECHPP) ProjectNew-National Center for HIV/AIDS, 

Viral Hepatitis, STD, and TB Prevention 

(NCHHSTP), Centers for Disease Control 

and Prevention (CDC). 

Background and Brief Description 

The scope of the HIV epidemic in the 

United States is significant, particularly 

in large urban areas where HIV/AIDS 

cases are concentrated. In 2006, 

approximately 56,000 new HIV 

infections occurred in the U.S., 

demonstrating the need to expand 

targeted HIV prevention efforts. In 2010, 

twelve U.S. metropolitan statistical 

areas (MSAs) received funding, through 

their city and state health departments, 

to conduct the Enhanced 

Comprehensive HIV Prevention 

Planning (ECHPP) project. These twelve 

MSAs (Atlanta, GA; Baltimore, MD; 

Chicago, IL; Dallas, TX; District of 

Columbia; Houston, TX; Los Angeles, 

CA; Miami, FL; New York City, NY; 

Philadelphia, PA; San Francisco, CA; 

and San Juan, PR) had the highest AIDS 

prevalence rates in the U.S. at the end 

of 2007, representing 44% of all U.S. 

AIDS cases. The purpose of ECHPP is to 

enhance existing HIV prevention 

services in these high prevalence areas 

and provide an optimal mix of 

evidence-based behavioral, biomedical, 

and structural interventions to have 

maximum impact on the HIV/AIDS 

epidemic at the community level. 

ECHPP goals are consistent with CDC’s 

Division of HIV/AIDS Prevention 

Strategic Plan for HIV Prevention and 

with the National HIV/AIDS Strategy: 

(1) Prevent new HIV infections, (2) 

increase linkage to, and impact of, 

prevention and care services for HIVpositive individuals, and (3) reduce 

HIV-related health disparities. 

To evaluate ECHPP, data will be 

collected through both existing CDC 

data sources and through new data 

collection activities. Existing CDC data 

sources will include HIV surveillance 

systems (e.g., National HIV Behavioral 

Surveillance System, Medical 

Monitoring Project) that routinely 

collect information about behavioral 

and clinical outcomes from at-risk target 

populations in the 12 MSAs. A new data 

collection activity is proposed through 

this project to collect information about 

behavioral and clinical outcomes from 

injection drug users, high-risk 

heterosexuals, and HIV-positive 

individuals who access medical care in 

six of the 12 ECHPP-funded MSAs. 

These MSAs are: District of Columbia; 

Houston, TX; Los Angeles, CA; Miami, 

FL; New York City, NY; and San 

Francisco, CA. The purpose of this new 

data collection activity is to monitor 

community-level outcomes of ECHPP 

and supplement HIV surveillance data 

routinely collected in these areas. 

Outcome data will be collected in these 

MSAs at two time points from 2011 to 

2014. 

Two surveys will be used in this 

project: (1) A community-based survey 

to be administered to injection drug 

users and high-risk heterosexuals, and 

(2) a clinic-based survey to be 

administered to HIV-positive 

individuals seeking care at clinics that 

provide HIV-related services. Both 

surveys will collect data on 

demographics, sexual behavior, alcohol 

and drug use history, HIV testing 

experiences, exposure to HIV 

prevention messages, and participation 

in HIV prevention activities. The clinic 

survey will also include questions about 

HIV treatment, treatment adherence, 

sources of care, and medical outcomes. 

For the community survey, we intend to 

recruit and screen 1500 injection drug 

users and 1500 high-risk heterosexuals 

using venue-based, convenience 

sampling methods. For the clinic 

survey, we intend to recruit and screen 

2400 HIV-positive individuals seeking 

HIV care at medical clinics. A total of 

1200 eligible injection drug users (age ≥ 

18 yrs), 1200 eligible high-risk 

heterosexuals (age 18 to 60 yrs), and 

2400 eligible HIV-positive individuals 

(age ≥ 18 yrs) will be surveyed. CDC will 

collaborate with local health department 

staff and outreach workers in each MSA 

to identify venues and clinics 

appropriate for data collection. Surveys 

will be administered by trained, local 

interviewers. There is no cost to 

respondents other than their time. 

ESTIMATE OF ANNUALIZED BURDEN TABLE

Target population Data collection form Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total burden 

(in hours) 

Injection drug users ............................................ Community Screener ...... 500 1 5/60 42 

Eligible injection drug users ................................ Community Survey ......... 400 1 25/60 167 

High-risk heterosexual individuals ...................... Community Screener ...... 500 1 5/60 42 

Eligible high-risk heterosexual individuals .......... Community Survey ......... 400 1 25/60 167 

HIV-positive individuals ....................................... Clinic Screener ............... 933 1 5/60 78 


Emcdonald on DSK2BSOYB1PROD with NOTICES
Federal Register / Vol. 76, No. 64 / Monday, April 4, 2011 / Notices 18555 

ESTIMATE OF ANNUALIZED BURDEN TABLE—Continued 

Target population Data collection form Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total burden 

(in hours) 

Eligible HIV-positive individuals .......................... Clinic Survey .................. 800 1 25/60 333 

Total ............................................................. ......................................... ........................ ........................ ........................ 829 

Daniel Holcomb, 

Reports Clearance Officer, Centers for Disease 

Control and Prevention. 

[FR Doc. 2011–7886 Filed 4–1–11; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Disease, Disability, and Injury 

Prevention and Control Special 

Emphasis Panel (SEP): Initial Review 

The meeting announced below 

concerns Virologic Evaluation of the 

Modes of Influenza Virus Transmission 

among Humans, Funding Opportunity 

Announcement (FOA), IP11–001, initial 

review. 

In accordance with Section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC) 

announces the aforementioned meeting: 

Time and Date: 8 a.m.–5 p.m., May 17, 

2011 (Closed). 

Place: Sheraton Gateway Hotel Atlanta 

Airport, 1900 Sullivan Road, Atlanta, Georgia 

30337, Telephone: (770) 997–1100. 

Status: The meeting will be closed to the 

public in accordance with provisions set 

forth in Section 552b(c)(4) and (6), Title 5 

U.S.C., and the Determination of the Director, 

Management Analysis and Services Office, 

CDC, pursuant to Public Law 92–463. 

Matters to be Discussed: The meeting will 

include the initial review, discussion, and 

evaluation of applications received in 

response to ‘‘Virologic Evaluation of the 

Modes of Influenza Virus Transmission 

among Humans, FOA IP11–001.’’ 

Contact Person for More Information: 

Gregory Anderson, M.S., M.P.H., Scientific 

Review Officer, CDC, 1600 Clifton Road, NE., 

Mailstop E60, Atlanta, Georgia 30333, 

Telephone: (404) 498–2293. 

The Director, Management Analysis and 

Services Office, has been delegated the 

authority to sign Federal Register notices 

pertaining to announcements of meetings and 

other committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Dated: March 29, 2011. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. 2011–7883 Filed 4–1–11; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Disease, Disability, and Injury 

Prevention and Control Special 

Emphasis Panel (SEP): Initial Review 

The meeting announced below 

concerns Economic Studies of Vaccines 

and Immunization Policies, Programs, 

and Practices, Funding Opportunity 

Announcement (FOA), IP11–007, initial 

review. 

In accordance with Section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC) 

announces the aforementioned meeting: 

Time and Date: 12 p.m.–2 p.m., June 14, 

2011 (Closed). 

Place: Teleconference. 

Status: The meeting will be closed to the 

public in accordance with provisions set 

forth in Section 552b(c) (4) and (6), Title 5 

U.S.C., and the Determination of the Director, 

Management Analysis and Services Office, 

CDC, pursuant to Public Law 92–463. 

Matters to be Discussed: The meeting will 

include the initial review, discussion, and 

evaluation of applications received in 

response to ‘‘Economic Studies of Vaccines 

and Immunization Policies, Programs, and 

Practices, FOA IP11–007, initial review.’’ 

Contact Person for More Information: Amy 

Yang, PhD, Scientific Review Officer, CDC, 

1600 Clifton Road, NE., Mailstop E60, 

Atlanta, Georgia 30333, Telephone: (404) 

498–2733. 

The Director, Management Analysis and 

Services Office, has been delegated the 

authority to sign Federal Register notices 

pertaining to announcements of meetings and 

other committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Dated: March 29, 2011. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. 2011–7882 Filed 4–1–11; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

Statement of Organization, Functions, 

and Delegations of Authority 

Part F of the Statement of 

Organization, Functions, and 

Delegations of Authority for the 

Department of Health and Human 

Services, Centers for Medicare & 

Medicaid Services (CMS), (Federal 

Register, Vol. 75, No. 56, pp. 14178, 

dated Wednesday, March 24, 2010) is 

amended to reflect updates to the 

functions for the Center for Strategic 

Planning (FCK). 

Part F. is described below: 

• Section FC. 20. (Functions) reads as 

follows: 

Center for Strategic Planning (FCK) 

• Provide senior leadership over the 

strategic planning process and the 

development of CMS strategic goals, 

metrics, and plans. 

• Direct the development of financial 

and health care trend analysis and 

management insight report to inform 

senior CMS leadership strategic 

decision making. 

• Set priorities for CSP direction, 

budget, personnel, and staff 

development. 

• Translate statistical data into 

information useful to agency leadership. 

• Provide leadership to the 

development of performance 

dashboards and databases for key 

agency initiatives. 

• Provide leadership in maintaining 

and ensuring quality of data resources 

needed for testing and evaluating 

demonstrations and innovations. 

• Direct the development of 

enterprise business plans, process 

requirement for CMS post ACA 


Emcdonald on DSK2BSOYB1PROD with NOTICES